Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pacira BioSciences's 5-Year RORE % for the quarter that ended in Mar. 2026 was 495.12%.
The industry rank for Pacira BioSciences's 5-Year RORE % or its related term are showing as below:
FRA:82P's 5-Year RORE % is ranked better than 99.09% of 881
companies
in the Drug Manufacturers industry
Industry Median: 1.37
vs FRA:82P: 495.12
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pacira BioSciences 5-Year RORE % Related Terms
Pacira BioSciences 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: 5-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences 5-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Pacira BioSciences (FRA:82P) has a 5-Year RORE % of 495.12 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Pacira BioSciences and its competitors. According to the industry distribution chart, Pacira BioSciences ranks #8 out of 881 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Pacira BioSciences' 5-Year RORE % too high?
Pacira BioSciences' current 5-Year RORE % is 495.12. The Drug Manufacturers industry median 5-Year RORE % is 1.37. Pacira BioSciences' value of 495.12 is 36040.1% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #8 out of 881 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' 5-Year RORE % compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #8 out of 881 companies for 5-Year RORE %. This places Pacira BioSciences in the top 1% of its industry — outperforming the majority of peers. The industry median 5-Year RORE % is 1.37. Pacira BioSciences' value of 495.12 is 36040.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Drug Manufacturers company?
The median 5-Year RORE % among Drug Manufacturers companies is 1.37, based on 881 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current 5-Year RORE % of 495.12 is 36040.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median 5-Year RORE % is 1.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current 5-Year RORE % is 495.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current 5-Year RORE % of 495.12. The stock's GF Value™ is €25.64, compared to a current price of €22.00 — trading 14.2% below its estimated fair value. The current 5-Year RORE % is 495.12 and 36040.1% above the Drug Manufacturers industry median of 1.37. Pacira BioSciences' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current 5-Year RORE % is 495.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.00 is trading 14.2% below its estimated GF Value™ of €25.64.
Key valuation signals for FRA:82P:
5-Year RORE %: 495.12
GF Value™: €25.64 vs. price of €22.00 (14.2% below fair value)
Industry Position: 36040.1% above the Drug Manufacturers median (#8 of 881)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
79GF Score
Get the complete analysis for FRA:82P
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
